KNOXVILLE, TN, July 19, 2022 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Kelly Tseng, PhD, Associate Professor of Pathology and Lab Medicine, School of Life Sciences at the University of Nevada, Las Vegas (UNLV) to characterize the effects of Provectus’ pharmaceutical-grade rose bengal sodium (RBS) on vertebrate tissue regeneration and repair. RBS is the lead member of a class of small molecules called halogenated xanthenes that is entirely owned by Provectus.
The Tseng Lab at UNLV will assess the effects of RBS on animal development and tissue repair using the African clawed frog (Xenopus laevis), an established vertebrate model organism, and in vivo assays to evaluate key biological processes: embryo development, wound healing, and tissue regeneration.
Dr. Tseng is an expert in tissue regeneration and a leader in the regenerative biology and bioelectrical signaling fields. Her research group at UNLV seeks to elucidate the mechanisms of complex tissue regeneration in vertebrates using the highly regenerative clawed frog, with the goal of applying this knowledge to therapeutic strategies. Dr. Tseng has identified key factors that control limb and eye regeneration, and has also established a new model for studying embryonic eye stem cells.
She graduated from the Massachusetts Institute of Technology with a Bachelor of Science in Biology and Harvard University with a PhD, and was a Howard Hughes Medical Institute research fellow at Boston Children's Hospital. Dr. Tseng's work has been highlighted in books and media outlets including The New York Times.
Recent medical journal publications of hers include “From Cell Death to Regeneration: Rebuilding After Injury” (Front Cell Dev Biol 18;9:655048. 2021), “Studying in vivo Retinal Progenitor Cell Proliferation in Xenopus laevis” (Retinal Development. Methods in Molecular Biology, 2092:19-33. 2020), and “Using the Xenopus Developmental Eye Regrowth System to Distinguish the Role of Developmental Versus Regenerative Mechanisms” (Front Physiol 10:502. 2019).
About Provectus
Provectus Biopharmaceuticals, Inc. (Provectus or the Company) is a clinical-stage biotechnology company developing immunotherapy medicines for different disease areas based on a class of small molecules called halogenated xanthenes (HXs). The Company’s lead molecule is RBS. A second HX molecule has been synthesized.
Provectus’ drug discovery and development programs include investigational drugs and drug targets in oncology (clinical-stage), dermatology (clinical-stage), hematology, virology, microbiology, ophthalmology (clinical-stage), animal health, and tissue regeneration and repair, and use multiple routes of administration, such as intralesional (IL), topical (.top), oral (P.O.), inhaled (.inh), intranasal (IN), and intravenous (IV).
Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, www.clinicaltrials.gov. For additional information about Provectus, please visit the Company's website at www.provectusbio.com.
FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook.
The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels.
Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement.
Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of:
- The Company’s Annual Report on Form 10-K for the period ended December 31, 2021, and
- Provectus’ Quarterly Report on Form 10-Q for the period ended March 31, 2022.
#####
Contact:
Provectus Biopharmaceuticals, Inc.
Heather Raines, CPA
Chief Financial Officer
Phone: (866) 594-5999
